Search:

Login | Subscribe

Home > Companies > Synairgen

Price	Market	Sector	Market Cap
17.00p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£3.81m

Add to company folder | Print

Related Companies

AGY	10.00p	0.00%
APH	4.62p	0.00%
AZH	p
BBI	p
CEN	p
CBF	2.25p	0.00%
COT	93.00p	0.54%
CRX	2.75p	0.00%
CYX	p
LAC	p
EVC	25.75p	0.00%
FUL	3.12p	0.00%
FUM	29.00p	7.41%
GMX	1.75p	0.00%
GNI	p
GWP	30.00p	3.45%
HML	0.42p	0.00%
MLR	p
MMG	7.25p	0.00%
MPM	14.25p	0.00%

Commentary

Drug developer aiming to focus on causes of asthma and chronic obstructive pulmonary disease

Recent Articles

Healthy demand for drug developers	30/03/2005
Christopher Spink's Pick of AIM	30/03/2005

Recent Announcements

Result of AGM	13/11/2008
Change of NOMAD	07/11/2008
Total Voting Rights	31/10/2008
Director/PDMR Shareholding and Additional Listing	20/10/2008
Posting of 2008 Annual Report	10/10/2008
Change of Adviser Name	08/10/2008
Research Update	22/09/2008
Director/PDMR Shareholding	04/08/2008
Final Results	31/07/2008
Commencement of Clinical Tria	29/07/2008
More

Articles from the Sector

Stroke hope at ReNeuron	28/11/2008
Futura Medical	28/11/2008
Option deal boosts ImmuPharma	25/11/2008
Digital imager targets AIM	24/11/2008
Vectura loses interim £11.7m	24/11/2008
GW trims loss	19/11/2008
Asterand	18/11/2008
EU trial cheers Plethora	07/11/2008
IS Pharma	05/11/2008
Animalcare nurturing high-margin growth	03/11/2008
More

Financial History

Financial Year End	30/06/2005	30/06/2006	30/06/2007	30/06/2008
Currency	GBP	GBP	GBP	GBP
Turnover	0.20	0.08	0.08	0.00
Operating Profit	-0.91	-1.68	-2.23	-2.76
Pretax Profit	-0.61	-1.30	-1.89	-2.47
Earnings After Tax	-0.61	-1.05	-1.64	-2.15
Profit Available For Dividend	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00
Retained Profit	-0.61	-1.05	0.00	0.00
Shareholders Funds	8.84	7.84	6.25	4.19
Net Current Assets	8.66	7.65	0.00	0.00
Adjusted Earnings Per Share Undiluted	-3.26	-4.84	-7.56	-9.92
Adj Earnings Per Share	-3.26	-4.84	-7.56	-9.92
Dividend Per Share	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	Mailpoint 810, Level F, South Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD
Telephone	023 8051 2800
Fax	023 8051 2800
Executives
Chairman	Simon Shaw (3.70% holding)
Managing Director	Richard Marsden (5.10% holding)
Finance Director	John Ward (2.40% holding)
Non-Exec Director	Stephen Holgate (3.90% holding)
Main Shareholders
	IP2IPO Group: 29.6% Southampton Asset Management: 16.6% Lansdowne Partners: 9% AMVESCAP: 6.1%
Advisers
Nominated Adviser	Teathers
Nominated Broker	Teathers
Solicitors	Fasken Martineau
Auditors	BDO Stoy Hayward
Registrar	Capita Registrars

Commentary
Drug developer aiming to focus on causes of asthma and chronic obstructive pulmonary disease
Company Data
Code	SNG
Sedol	GB00B0381Z
Shares In Issue	22.392 m
Indices
Entry on AIM	26/10/2004
Interim Results	Mar
Final Results	Jul
Year End	Jun
Accounts Due	Oct
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes